R&D channel feed – Endpoints News

R&D channel feed

After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients

6 years ago

Celgene's AML drug clears late-stage test

6 years ago

It's not perfect, but it's a good start: FDA panelists largely endorse Aimmune's peanut allergy therapy

6 years ago

Ritter bombs final PhIII for sole lactose intolerance drug — shares plummet

6 years ago

Early snapshot of Adverum's eye gene therapy sparks concern about vision loss

6 years ago

Ardelyx bags its first FDA OK for IBS, setting up a showdown with Allergan, Ironwood

6 years ago

It’s finally over: Biogen, Eisai scrap big Alzheimer’s PhIIIs after a predictable BACE catastrophe raises safety fears

6 years ago

Another pharma giant makes a leap into the global medical marijuana business

6 years ago

FDA slaps a hold on one of Amgen’s early-stage cancer drugs, raising cardiac tox concerns for a top prospect in the pipeline

6 years ago

MSK picks brain cancer expert Lisa DeAngelis as its next CMO — following José Baselga’s controversial exit

6 years ago

Roche's Tecentriq excels in another lung cancer study

6 years ago

Penn team adapts CAR-T tech, reengineering mouse cells to treat cardiac fibrosis

6 years ago

J&J's head-to-head PhIII data promise drug launch into crowded MS market

6 years ago

Tocagen shares collapse as investigators read last rites for PhIII brain cancer study

6 years ago

Look out Alexion, Roche breaks out the details on its rival rare CNS drug

6 years ago

The mRNA unicorn Moderna has more early-stage human data it wants to show off — reaching new peaks in proving the potential

6 years ago

Promising autoimmune biotech bought out as celiac drug heads for the clinic with a fresh infusion of cash

6 years ago

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

6 years ago

Merck KGaA touts FDA 'breakthrough' status, blockbuster potential in bid to woo investors

6 years ago

Woodford fallout to blame for shrinking biotech valuations, co-investor says

6 years ago

Sanofi takes a $260M hit to extricate itself from a disastrous alliance with Lexicon

6 years ago

After BioCryst fizzle, a new oral HAE player emerges

6 years ago

Australian cell therapy company Mesoblast joins forces with Germany's Grünenthal to tackle low back pain

6 years ago

A new player jumps into the heated race for a sickle cell cure, with help from Google's GV

6 years ago

First page Previous page 232 233 234235236 237 238 Next page Last page